Clay Siegall Develops Modernized Therapies for Cancer Treatment


Being one of the world’s primary medical problems, cancer has attracted many scientists and physicians globally. The core objective of these doctors is finding treatment. One of the scientists who has made a name for themselves in the field of cancer research center and treatment is Clay Siegall. Following his strong academic background and research, Clay Siegall has significantly contributed to the fight against all types of cancer. Dr. Clay Siegall is the co-founder of Seattle Genetics; an emerging biotech company focused on revolutionizing cancer treatment across the world. He is a scientist by training and since 1998; he has been Seattle Genetics’ President and Chief Executive Officer. Clay is also Chairman of the board.

Seattle Genetics

Seattle Genetics emphasizes on modernized cancer therapies. It was established from scientific innovation, extensive research and drug generation practices aimed at assisting patients. Through Clay’s leadership, Seattle Genetics has been able to provide antibody-drug conjugates for cancer therapies. Additionally, the cancer research center has been able to secure an approval of the 2011 FDA, ADC product. Following its collaboration with Takeda Pharmaceutical, Seattle Genetics managed to introduce ADCETRIS brand into the market, for further treatment in cancer. Over 65 countries have the approval of ADCETRIS. Seattle Genetics commits to advancing an extensive channel of proprietary ADCs for cancer treatment.

Clay Siegall’s’ Contribution

With the contribution of Dr. Siegall, Seattle Genetics has been able to enter into several strategic licenses linked to ADC. It has also collaborated with Genentech, GlaxoSmithKline (Gsk), Pfizer and AbbVie in the fight against cancer. Bordering international programs, over 20 ADCs have been linked to clinical development procedures in cancer treatment. Additionally, Dr. Clay Siegall has geared Seattle Genetics resources to secure over $1.2 billion in public and private money lending institutions.

About Clay Siegall

Clay is the President and Chief Executive Officer of Seattle Genetics. He attended the University of Maryland and graduated with a bachelor’s degree in Science, having majored in Zoology. Clay advanced his knowledge and skills in the University of George Washington. He studied Genetics before joining the cancer research center.

Leave a Reply

Your email address will not be published. Required fields are marked *